Stock Events

Stock Events

PhaseBio Pharmaceuticals

0

0

+€0.00+0% 00:00 Today

Statistics

Day High

-

Day Low

-

52W High

-

52W Low

-

Volume

-

Avg. Volume

-

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen is a biotechnology company that develops and manufactures innovative human therapeutics, including treatments for cardiovascular diseases, which competes with PhaseBio's focus on cardiopulmonary disorders.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals focuses on developing medications for serious medical conditions, including cardiovascular diseases, directly competing with PhaseBio's product pipeline.

Novo Nordisk is a global healthcare company with a strong focus on diabetes and obesity management, but also on hemostasis management, which overlaps with PhaseBio's interest in bleeding disorders.

Bristol-Myers Squibb

Bristol Myers Squibb is involved in discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases, including areas like cardiovascular health, competing with PhaseBio's therapeutic areas.

Pfizer is a global pharmaceutical corporation with a broad range of products in various therapeutic areas, including cardiovascular diseases, making it a competitor to PhaseBio.

AstraZeneca operates in several therapeutic areas, including cardiovascular, renal, and metabolism, directly competing with PhaseBio's focus areas.

Merck is known for its contributions to healthcare, including cardiovascular disease treatments, positioning it as a competitor to PhaseBio.

Sanofi focuses on a broad spectrum of therapeutic areas, including cardiovascular diseases, which makes it a direct competitor to PhaseBio.

Johnson & Johnson

Johnson & Johnson, through its Janssen Pharmaceuticals companies, develops treatments for a wide range of health conditions, including cardiovascular diseases, competing with PhaseBio.

AbbVie has a diverse line of therapies, including interest in cardiovascular diseases, making it a competitor to PhaseBio in the pharmaceutical landscape.

About

PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.

Show more...

CEO

Jonathan Mow

Employees

60

Country

United States

ISIN

US7172241090

Listings

0 Comments

Share your thoughts

FAQ

What is PhaseBio Pharmaceuticals stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange PhaseBio Pharmaceuticals stocks are traded under the ticker 2K4.MU.

How many employees does PhaseBio Pharmaceuticals have?▼

As of July 13, 2026, the company has 60 employees.

In which sector is PhaseBio Pharmaceuticals located?▼

PhaseBio Pharmaceuticals operates in the Manufacturing sector.

When did PhaseBio Pharmaceuticals complete a stock split?▼

PhaseBio Pharmaceuticals has not had any recent stock splits.

Where is PhaseBio Pharmaceuticals headquartered?▼

PhaseBio Pharmaceuticals is headquartered in Malvern, United States.